32 results about "Immune serums" patented technology

The invention discloses a conservative B cell epitope peptide of goose parvovirus VP3 protein, a nucleic acid molecule, a recombinant vector and application thereof. Conservative B cell epitope EW12 is inserted into F18 Escherichia coli Fod fimbriae, inert carrier bacteria S9H are introduced, recombinant bacteria capable of functionally exhibiting and expressing the EW12 conservative B cell epitope on the surface of the bacteria are obtained, the recombinant bacteria can specifically generate specific binding reaction with gosling plague egg yolk antibody and gosling plague vaccine immune serum, and the gosling plague egg yolk antibody and the gosling plague vaccine immune serum can be specifically combined with the gosling plague egg yolk antibody and the gosling plague vaccine immune serum. The method has the advantages that macroscopic agglutination particles are generated, cross agglutination reaction with other pathogen positive serum and healthy goose serum is avoided, the method is good in sensitivity, and the specific antibody can be detected in the 5th day after immunization at the earliest. A plate agglutination test directly mediated by the goose parvovirus VP3 protein conservative B cell epitope peptide EW12 has the advantages of specificity, sensitivity, convenience in operation and suitability for on-site large-scale rapid detection, and is expected to provide a new technical means for diagnosis, prevention and control and purification of GPV infection.

The invention belongs to the technical field of molecular biology, and discloses a truncated outer membrane protein of klebsiella pneumoniae and application thereof. The invention provides an outer membrane protein Lol B of klebsiella pneumoniae, which can be used for immunizing to induce a protective antibody aiming at various serotypes of klebsiella pneumoniae and killing the klebsiella pneumoniae. Specifically, the outer membrane protein Lol B immune serum can efficiently kill Klebsiella pneumoniae, and when a mouse immunized by the outer membrane protein Lol B immune serum is attacked by K1, K2 and K6 serotype Klebsiella pneumoniae, the mouse can be completely protected to survive, and the trend of weight loss of the mouse is remarkably reduced. Therefore, the outer membrane protein Lol B provided by the invention has a clinical application value for preventing and treating klebsiella pneumoniae infection.

A general formula for lysins based on which the activity and functionality are further screened and 24 lysins are identified and further investigated, nine of which are characterized. These lysins exhibit potent bactericidal activity, capable of lysing multiple species of Staphylococcus, Streptococcus, and / or Enterococcus; demonstrate robust environmental resistance and stability, retaining activity under varying temperatures, NaCl concentrations, pH levels, and in immune serum; and effectively treat localized and systemic infections. These lysins and their variants are promising as antimicrobial agents for eradicating bacteria, preventing bacterial infections, or treating bacterial infections (caused by genera Staphylococcus, Streptococcus, and / or Enterococcus).

The application discloses a kind of areca alkaloid artificial hapten, artificial antigen and its preparation method and application, with norarecoline hydrochloride as the starting material for synthesizing artificial hapten.This areca alkaloid artificial hapten retains the characteristic structure of areca alkaloid to the greatest extent, and has active groups that can couple with carrier proteins, which can be used as antigenic determinants;Further, the areca alkaloid artificial antigen obtained can be used to immunize to obtain an anti-areca alkaloid artificial antibody with high affinity, high sensitivity and strong specificity.The titer of the immune serum obtained by immunizing New Zealand white rabbits is as high as 1:70000, and can be used for rapid and accurate immunodetection and immunoassay of areca alkaloid.

The invention discloses a polyclonal antibody of panda Rbp7 protein as well as a preparation method and application thereof, and belongs to the technical field of antibodies. The first to nineteenth amino acid sequences of the panda Rbp7 protein are used as antigen polypeptides, and are specifically shown as SEQ ID No.1. After chemical synthesis or exogenous expression purification, a Balb / C mouse is immunized, and the polyclonal antibody is obtained through repeated immunization, serum titer detection and affinity chromatography purification. The titer of the antibody is not lower than 1 / 128000, the panda Rbp7 recombinant protein can be efficiently and specifically detected through WB and ELISA, the blank of a protein detection tool is filled, and reliable technical support is provided for research on the functional mechanism of the panda Rbp7 protein.

The application discloses a method for improving the sensitivity of a porcine circovirus type 2 Cap protein antigen agar diffusion detection, and belongs to the technical field of veterinary products. The method is as follows: (1) inoculating piglets with a porcine circovirus 2a, 2b and 2d trivalent virus-like particle vaccine, and then separating serum to obtain a porcine circovirus 2a, 2b and 2d trivalent high-immune serum; (2) preparing a high-salt agar plate; (3) diluting the trivalent high-immune serum and the porcine circovirus type 2 Cap protein antigen with a high-salt diluent, respectively, and then adding the diluted trivalent high-immune serum and the porcine circovirus type 2 Cap protein antigen into holes of the agar plate, and incubating at 35-37 DEG C for 20-24 h to complete the detection. The application uses high-immune serum and an improved agar diffusion method to quantitatively detect the content of PCV2 Cap protein, and avoids the defects of low tolerance to buffer reagents and poor detection specificity of the commonly used BCA or Bradford protein content detection method.

The application discloses a colloidal gold test strip for distinguishing between wild toxin infection and vaccine immunization of porcine pleuropneumonia actinobacillus and application. The test strip of the application takes ApxIVA truncated protein with an amino acid sequence shown as SEQ ID NO. 3 as an antigen, the truncated protein can be soluble expressed in E. coli, and the structure and function of the truncated protein are close to those of natural apxIVA. The test strip of the application comprises a sample pad, a colloidal gold pad, an NC membrane, a water absorption filter paper and a bottom plate, the colloidal gold pad is coated with gold-labeled apxIVA truncated protein and gold-labeled chicken IgY antibody, and the C line and the T line of the NC membrane are fixed with goat anti-chicken IgY antibody and apxIVA truncated protein. The test strip only needs 25 muL of pig serum to make detection within 5-10 min, and can distinguish between APP wild strain infection and gene deletion vaccine APP-HB-04M immunized serum samples.

The present invention belongs to the field of biochemical technology, and specifically relates to an artificial hapten and an artificial antigen for benzhexyphenidyl, as well as a preparation method and application thereof. The molecular structural formula of the artificial hapten for benzhexyphenidyl is shown in Formula (I), and the molecular structural formula of the artificial antigen for benzhexyphenidyl is shown in Formula (II). The artificial hapten for benzhexyphenidyl can be used in the field of preparing anti-benzhexyphenidyl antibodies. The artificial hapten for benzhexyphenidyl of the present invention retains the characteristic structure of benzhexyphenidyl to the greatest extent, and has an active group that can be coupled with a carrier protein, and can serve as an antigenic determinant. The artificial hapten for benzhexyphenidyl obtained by further preparation can be used to immunize and obtain anti-benzhexyphenidyl antibodies with high affinity, high sensitivity, and strong specificity. The titer of the immune serum obtained by immunizing New Zealand white rabbits is as high as 1:256,000, and can be used for rapid and accurate immunodetection and immunoanalysis of benzhexyphenidyl.

The present application belongs to the technical field of bio-chemical industry, and particularly relates to a lorcaserin artificial hapten, a lorcaserin artificial antigen, and a preparation method and application thereof. The lorcaserin hydrochloride is used as a starting material for synthesizing the artificial hapten, the lorcaserin artificial hapten of the present application retains the characteristic structure of lorcaserin to the greatest extent, and has an active group which can be coupled with a carrier protein, and can be used as an antigenic determinant; the lorcaserin artificial antigen prepared further can be used for immunization to obtain an anti-lorcaserin artificial antibody with high affinity, high sensitivity and high specificity, the titer of the immune serum obtained by immunizing a New Zealand white rabbit is as high as 1:256000, and the immune serum can be used for rapid and accurate immunodetection and immunological analysis of lorcaserin.

The invention discloses a diagnostic method based on mouse lyme disease serology indirect ELISA laboratory, and relates to the technical field of immunoserology detection.The diagnostic method comprises the steps that experimental conditions are optimized through a system, and the optimal reaction system is determined as follows: the antigen coating concentration is 0.2 microgram / microliter, the serum dilution ratio is 1: 200, and the enzyme-labeled secondary antibody concentration is 1: 2000. 0.8), and meanwhile, the antigen dosage is obviously reduced. Dynamic analysis of the antibody shows that the level of the antibody infecting mouse serum reaches a peak 12-25 days after inoculation, and the threshold value of the specific antibody ratio (ArB%) is 71.43%. Researches prove that the method has the characteristics of simplicity and convenience in operation, economy and high efficiency, and is suitable for primary laboratories and large-scale screening. The method provides reliable standardized technical support for lyme disease laboratory diagnosis and epidemiological monitoring.

The utility model discloses a polyclonal antibody immune serum vacuum blood sampling device, and relates to the technical field of blood sampling instruments, the polyclonal antibody immune serum vacuum blood sampling device comprises a blood sampling tube, the upper end and the lower end of the blood sampling tube are not sealed, the upper end opening of the blood sampling tube is connected with an end cover in a clamping mode, the end cover comprises a cover shell, and the cover shell is provided with a sealing cover. A cover shell is arranged in the blood collection tube, a leather plug is embedded in the cover shell, the leather plug is made of an antibacterial elastic material, an airtight self-inspection piece is clamped to a lower end opening of the blood collection tube, the airtight self-inspection piece comprises a transparent sealing shell, and a transparent sealing plug is embedded in the transparent sealing shell. The vacuum degree in the blood collection tube is visually reflected through the elastic membrane cloth, when the elastic membrane cloth deforms, the guide rod and the indicator at the bottom of the guide rod are driven to move together, and the color indication mark is arranged on the indication strip, so that the blood collection tube is convenient to use. And the vacuum degree in the blood sampling tube can be checked by observing the color interval of the indicator on the indication strip.

The application belongs to the technical field of antibodies, and particularly relates to an antibody for specifically treating orf of milk goat kids and application thereof. Virus liquid of a diseased goat is collected from a lesion site, and ORFV virus strains are obtained through subculture and amplification of goat skin fibroblasts; milk goats are immunized with a weak vaccine to prepare high-titer immune serum; flow sorting technology is used to separate ORFV-specific B cells from PBMC (peripheral blood mononuclear cells); antibody genes are amplified through nested PCR, expression vectors are constructed, and 293T cells are transfected to express monoclonal antibodies. The monoclonal antibody No. 2 obtained in the application has high affinity and specificity, the heavy chain CDR1-3 region sequence is SEQ ID NO: 1-3, and the light chain CDR1-3 region sequence is SEQ ID NO: 4-6. The antibody can be used for diagnosis, treatment and prevention of orf of goats, and has the characteristics of high efficiency, specificity and stability, and provides a new biological preparation for prevention and control of orf of goats.

The invention discloses a monospecific monoclonal antibody for resisting zearalenone-14 glucoside and application of the monospecific monoclonal antibody. An immunogen and a coating antigen are used; the monoclonal antibody capable of monospecifically recognizing the zearalenone-14 glucoside and the rapid detection kit for detecting the zearalenone-14 glucoside are obtained through the technologies of mouse immunization, serum detection, cell fusion, monoclonal screening, ascites induced antibody and the like. The method is suitable for single-specificity trace residue detection of the zearalenone-14 glucoside in samples such as corn, rice, millet, wheat and oat, has very high recognition sensitivity to the zearalenone-14 glucoside, and realizes rapid, large-batch and low-cost detection of the zearalenone-14 glucoside.

The application discloses a monoclonal antibody of immune serum antibody for O-type foot-and-mouth disease virus and application thereof, and relates to the technical field of animal virology and animal infectious disease detection. The application uses vp1 protein as an immunogen, uses polypeptides containing B cell antigen epitopes and inactivated antigens as screening origins respectively, screens out monoclonal antibodies capable of competing with O-type foot-and-mouth disease virus inactivated vaccine and synthetic peptide vaccine immune background serum, and establishes an O-type foot-and-mouth disease virus solid-phase competitive ELISA kit, which greatly shortens the detection time and improves the sensitivity, specificity and stability of the kit.

The invention discloses a B cell epitope peptide based on human papilloma virus E6 protein and application of the B cell epitope peptide in cancer diagnosis. According to the invention, the epitope peptide is displayed and expressed on the surface of an inert carrier bacterium S9H, so that an RI5 epitope peptide-antibody direct mediated agglutination test detection system based on thallus surface epitope display is successfully constructed. Compared with an immunoserological detection technology based on a complete protein antigen, the kit provided by the invention can be used for more specifically, sensitively, conveniently and quickly detecting the virus oncoprotein specific antibody in the body of an HPV persistent infection patient, and can be used for qualitatively and quantitatively determining the content of the antibody. The epitope peptide-antibody direct mediation agglutination test detection technology provides an efficient and reliable new method for accurate diagnosis of dynamic changes of virus oncoprotein antibodies in persistent infection and cancer stages of HPV patients, and has potential important clinical application value.

The application discloses a blocking agent for milk allergen component-specific IgE antibody test strips and application, and belongs to the technical field of immune detection and analysis. The blocking agent uses soybean protein isolate and fish gelatin as the blocking agent in antigen-antibody reaction of immunoserological technology, so as to reduce false negative results caused by using conventional blocking agents, casein and bovine serum albumin, and thus makes the detection result more accurate.

The invention provides a rabbit polyclonal antibody aiming at primary cilia and a preparation method thereof, and belongs to the technical field of biology, and the preparation method comprises the following steps: taking a 200-428 amino acid sequence of human ARL13B protein as a target fragment, synthesizing a gene after codon optimization, cloning the gene to a pet-32a expression vector, and carrying out induced expression in escherichia coli to obtain the rabbit polyclonal antibody aiming at primary cilia. Purifying to obtain high-purity immunogen protein; the nucleotide sequence of the synthetic gene is as shown in SEQ ID NO.1, and the amino acid sequence of the high-purity immunogen protein is as shown in SEQ ID NO.2. Immunizing a New Zealand white rabbit with the high-purity immunogen protein to obtain immune serum; and purifying the immune serum to obtain the rabbit polyclonal antibody. The prepared rabbit polyclonal antibody has higher specificity and signal strength, the titer can reach 1: 64000 or above through ELISA detection, primary cilia can be marked more clearly in a paraffin section immunofluorescence experiment, background noise is remarkably reduced, and the reliability of an experiment result is improved.

The present application belongs to the technical field of bio-chemical industry, and particularly relates to a nafurexone artificial hapten, an artificial antigen, and a preparation method and application thereof. The nafurexone artificial hapten of the present application retains the characteristic structure of nafurexone to the greatest extent, and has an active group that can be coupled with a carrier protein, and can be used as an antigenic determinant. The nafurexone artificial antigen prepared further can be used to immunize to obtain an anti-nafurexone polyclonal antibody with high affinity, high sensitivity and high specificity. The titer of the immune serum obtained by immunizing a New Zealand white rabbit is as high as 1:128000, and can be used for rapid and accurate immunodetection and immunological analysis of nafurexone.

The invention provides a nano antigen particle containing an influenza virus NA antigen, an influenza virus vaccine based on the nano antigen particle and application of the influenza virus vaccine. The nano antigen particle can induce an organism to generate a high-level NA specific antibody, and immune serum of the organism can effectively inhibit enzyme activity reaction of homotype NA protein, so that the nano antigen particle has the potential of being developed into influenza virus vaccines.

The application provides a SARS-related coronavirus universal antigen and a preparation method and application thereof, and belongs to the technical field of immunity. The candidate antigen prepared by the application has higher S309 antibody and detection serum binding activity, the titer of serum obtained by immunizing mice with the candidate antigen has higher cross-binding activity to VOCs than that of template antigen immunized serum; meanwhile, the candidate antigen immunized serum has the ability to block the combination of VOCs and ACE2. Therefore, the candidate antigen prepared by the application can become a potential universal antigen or combination for inducing cross-neutralization activity for preventing SARS-related coronavirus infection. The strategy of preparing the candidate antigen with cross-neutralization immunogenicity based on DNA Shuffling and membrane mutation antigen screening technology is expected to be applied to universal vaccine research and development. The candidate universal antigen prepared by the application has the potential to be developed into a SARS-related coronavirus universal vaccine.

The invention discloses a multi-epitope fusion protein for preventing infection of A-type to G-type clostridium perfringens and application, the multi-epitope fusion protein MVCP prepared by the invention is used for preventing infection of A-type to G-type clostridium perfringens of livestock and poultry, and the amino acid sequence of the fusion protein is as shown in SEQ ID NO: 1. Mouse experiments verify that hyper-immune serum prepared by using the fusion protein as an antigen can prevent infection of any one of A-type and G-type clostridium perfringens, meanwhile, after MVCP immunizes a female mouse, the female mouse can generate high-level IgG antibodies, the antibodies are effectively transmitted to a newborn mouse through milk, the newborn mouse obtains resistance to infection of the A-type clostridium perfringens, and the newborn mouse can be prevented from suffering from infection of the A-type clostridium perfringens. Therefore, the effectiveness of the protein in preventing young animals from being infected with clostridium perfringens is verified.

The invention belongs to the technical field of biochemical engineering, and particularly relates to a medetomidine artificial hapten, an artificial antigen as well as a preparation method and application of the medetomidine artificial hapten and the artificial antigen. The medetomidine artificial hapten maximally retains the characteristic structure of medetomidine, has an active group capable of being coupled with carrier protein, and can be used as an antigenic determinant; the medetomidine artificial antigen obtained by further preparation can be immunized to obtain an anti-medetomidine polyclonal antibody with high affinity, high sensitivity and strong specificity, the titer of immune serum obtained by immunizing a New Zealand white rabbit is as high as 1: 135000, and the medetomidine artificial antigen can be used for rapid and accurate immunodetection and immunoassay of medetomidine.

The application discloses a fentanyl artificial hapten, a fentanyl artificial antigen and a preparation method and application thereof. The fentanyl artificial hapten of the application retains the characteristic structure of fentanyl to the maximum extent, and has an active group which can be coupled with a carrier protein and can serve as an antigenic determinant; the fentanyl artificial antigen prepared further can be used for immunization to obtain an anti-fentanyl antibody with high affinity, high sensitivity and high specificity, and the titer of the immune serum obtained by immunizing a New Zealand white rabbit is as high as 1:85000. The antigen and antibody can be used for enzyme-linked immunoassay, immunochromatography and the like, have the characteristics of high sensitivity, high specificity, strong operability and the like, and can be used for screening and detection of fentanyl components in various complex samples.

The invention belongs to the field of veterinary biological products, and particularly relates to an O-type foot-and-mouth disease virus strain containing a VP1 T193A mutation site, a construction method of the O-type foot-and-mouth disease virus strain and application of the O-type foot-and-mouth disease virus strain in vaccine antigen escape research. According to the O-type foot-and-mouth disease virus mutant strain provided by the invention, threonine at the 193rd site of VP1 protein of a wild O-type foot-and-mouth disease virus strain is mutated into alanine. The amino acid sequence of the mutated VP1 protein is as shown in SEQ ID NO: 2. The lesion time, virus titer and growth curve of the mutant strain rVP1-T193A and rWT constructed by the invention are highly similar, but the neutralizing antibody titer of immune serum is reduced by 4.26 times, the corresponding r value is 0.23 and less than 0.3, and immune escape may be caused. Animal immune challenge protection experiments also prove that the VP1 T193A causes the FMDV to escape from vaccine immunity. The mutation significantly reduces the sensitivity of the virus to a neutralizing antibody, and can be used for researching a virus immune escape mechanism and optimizing vaccine design.

This disclosure relates to a method of expressing the receptor-binding domain (RBD) region of the coronavirus SARS-CoV-2 Spike protein in a highly native form that is strongly reactive to natural antibodies induced upon SARS-CoV-2 infection or vaccination of humans and that more efficiently binds the angiotensin-converting enzyme 2 (ACE2) receptor. This method fuses the RBD to the C-terminus of an N-terminal fragment of the gp70 protein (the surface protein (SU) of the Friend57 strain of murine leukemia viruses). This method of expression enhances the native folding of the RBD and increases its recognition by antibodies present in immune sera and its ability to interact with the ACE2 receptor. Further disclosed are methods of using this form of RBD for various purposes.

The invention discloses a recombinant chimeric protein and application thereof in preparation of a goatpox virus virus vaccine, and belongs to the technical field of biological medicines. The amino acid sequence of the recombinant chimeric protein is as shown in SEQ ID NO: 1, and the recombinant chimeric protein is formed by connecting four common B cell antigen epitopes of LSDV and GTPV in series through flexible connecting peptides. The protein can be subjected to efficient soluble expression through a prokaryotic expression system, can be specifically recognized by LSDV infected serum and GTPV immune serum, and has good immunogenicity. Animal experiments show that a subunit vaccine prepared by taking the protein as an immunogen can induce a mouse to generate a neutralizing antibody aiming at LSDV and GTPV, and after challenge, visceral viral load is remarkably reduced, tissue pathological damage is relieved, and effective immune protection is provided. As a safe and efficient subunit vaccine antigen, the recombinant chimeric protein provided by the invention has a wide application prospect in the aspect of preparing broad-spectrum goat pox virus virus vaccines.

The invention provides akabane disease virus recombinant NSs protein, a preparation method and a kit, and relates to the technical field of biology. Recombinant expression of the akabane disease virus NSs protein is realized, and on the basis, a set of indirect ELISA detection method and kit for the akabane disease virus antibody are established, so that not only can the detection of the akabane disease virus antibody be realized, but also the distinguishing of akabane disease virus immune serum and infected serum can be realized.

The invention discloses a monospecific anti-thiamethoxam monoclonal antibody and application thereof, the monoclonal antibody capable of recognizing thiamethoxam in a monospecific manner and a rapid detection kit for detecting thiamethoxam are obtained by using an immunogen and a coating antigen through the technologies of mouse immunization, serum detection, cell fusion, monoclonal screening, ascites induced antibody and the like. The method is suitable for single-specificity trace residue detection of thiamethoxam in lake water, beef, pork, spinach, eggs and other samples, has very high recognition sensitivity to thiamethoxam, and realizes rapid, large-scale and low-cost detection of thiamethoxam.

This invention discloses a method for preparing Akabane virus vaccine based on BEI inactivation and its application. This invention optimizes the BEI inactivation process for the AKAV_FS202301 Akabane virus strain, ensuring complete virus inactivation while effectively preserving the viral antigen structure. The prepared inactivated vaccine can induce high titers of neutralizing antibodies in experimental animals; specifically, the neutralizing antibody titer in rabbit immune serum is 5. 6 The neutralizing antibody titer in mouse immune serum was 5. 5 The obtained immune serum significantly reduced the viral RNA copy number of AKAV, inhibited viral replication activity, and significantly reduced the proportion of AKAV-infected positive cells. In summary, the Akabane virus vaccine provided by this invention achieves highly efficient antigen retention and significantly enhanced immune response, possessing advantages such as strong immunogenicity and significant viral inhibition effect, and has promising application prospects.

The invention discloses a preparation method and application of an akabane virus vaccine based on BEI inactivation. The BEI inactivation process is optimized aiming at the AKAVFS202301 akabane virus strain, so that the virus antigen structure is effectively reserved while the complete inactivation of the virus is ensured; the prepared inactivated vaccine can induce an experimental animal to generate a high-titer neutralizing antibody, the titer of the neutralizing antibody of rabbit immune serum is 56, the titer of the neutralizing antibody of mouse immune serum is 55, and the obtained immune serum can significantly reduce the virus RNA copy number of AKAV, inhibit virus replication activity and significantly reduce the proportion of positive cells infected with AKAV. In conclusion, the akabane virus vaccine provided by the invention realizes efficient antigen retention and remarkably enhanced immune response, has the advantages of strong immunogenicity, remarkable virus inhibition effect and the like, and has a good application prospect.